The NSL Chromatin-Modifying Complex Subunit KANSL2 Regulates Cancer Stem-like Properties in Glioblastoma That Contribute to Tumorigenesis.

NAZARENA E. FERREIRA-SOLARI; GUILLERMO VIDELA RICHARDSON; EVA SERNA; GUSTAVO SEVLEVER; FIORELLA S. BELFORTE; JOAQUÍN M. ESPINOSA; MIGUEL A. RIUDAVETS; FIORELLA S. BELFORTE; CAROLINA PEREZ-CASTRO; JOAQUÍN M. ESPINOSA; MIGUEL A. RIUDAVETS; CAROLINA PEREZ-CASTRO; LUCÍA CANEDO; MARIO ROSSI; HORACIO MARTINETTO; LUCÍA CANEDO; MARIO ROSSI; HORACIO MARTINETTO; NAZARENA E. FERREIRA-SOLARI; GUILLERMO VIDELA RICHARDSON; EVA SERNA; GUSTAVO SEVLEVER

CANCER RESEARCH

AMER ASSOC CANCER RESEARCH

Lugar: Philadelphia; Año: 2016 vol. 76 p. 5383 - 5394

0008-5472

KANSL2 is an integral subunit of the nonspecific lethal (NSL) chromatin-modifying complex that contributes to epigenetic programs in embryonic stem cells. In this study, we report a role for KANSL2 in regulation of stemness in glioblastoma (GBM), which is characterized by heterogeneous tumor stem-like cells associated with therapy resistance and disease relapse. KANSL2 expression is upregulated in cancer cells, mainly at perivascular regions of tumors. RNAi-mediated silencing of KANSL2 in GBM cells impairs their tumorigenic capacity in mouse xenograft models. In clinical specimens, we found that expression levels of KANSL2 correlate with stemness markers in GBM stem-like cell populations. Mechanistic investigations showed that KANSL2 regulates cell self-renewal, which correlates with effects on expression of the stemness transcription factor POU5F1. RNAi-mediated silencing of POU5F1 reduced KANSL2 levels, linking these two genes to stemness control in GBM cells. Together, our findings indicate that KANSL2 acts to regulate the stem cell population in GBM, defining it as a candidate GBM biomarker for clinical use.